Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

LANCASTER UNIVERSITY-PUBLIC HEALTH ENGLAND COLLABORATION

A new collaboration between Lancaster University and Public Health England will work on routine data pertaining to neurological emergency admissions in England. Professors Emsley and Knight are currently working on the first large scale analysis of neurological emergency admissions in England. 

GLP-1 RECEPTOR AGONISTS AS POTENTIAL TREATMENTS FOR STROKE

Dr Mark Maskery has published a systematic review of GLP-1 receptor agonists as potential treatments for ischaemic stroke in the Journal of Cerebral Blood Flow and Metabolism.

work presented at association of british neurologists meeting

Work by Lancashire Neuroscience researchers on neurology informatics (PhD student Fran Biggin) and the risk of stroke after late-onset epilepsy (Academic Clinical Fellow in Neurology Dr Jasmine Wall) is being presented at the Association of British Neurologists Autumn 2020 virtual conference.

COCHRANE REVIEW HIGHLIGHTS POTENTIAL OF GLP-1 RECEPTOR AGONISTS FOR PARKINSON'S

A recent Cochrane review by Professor Emsley and colleagues at Lancaster University has highlighted the potential of GLP-1 receptor agonists (currently used to treat type 2 diabetes mellitus) as neuroprotective treatments for Parkinson's disease. Dr Richard Wyse (of The Cure Parkinson's Trust) co-authored the report. 

PhD STUDENT WORK PRESENTED AT NORTH OF ENGLAND NEUROLOGICAL ASSOCIATION MEETing

Work supervised by Professor Emsley entitled "Routinely collected patient data in neurology research: A systematic mapping review" was presented at the North of England Neurological Association at their annual meeting in November in Harrogate.  

LUMBAR PUNCTURE GUIDELINE ADOPTED AS NATIONAL GUIDELINE

Lumbar puncture is commonly used in neurology practice and is used to check the fluid that circulates around the brain and the spinal cord in order to diagnose disorders of the central nervous system. The guideline provides recommendations about lumbar puncture in patients on blood thinning medications. Click here to find out more

Discovery of magnetite nanoparticles from air pollution in human brain tissue, raising a potential link with Alzheimer’s disease

Prof David Allsop (Faculty of Health & Medicine, Lancaster University) & Prof Barbara Maher (Lancaster Environment Centre, Lancaster University). This finding was widely reported in the media in 2016 – including https://theconversation.com/how-we-discovered-a-possible-link-between-car-exhausts-and-alzheimers-64779

Inhibiting aggregation of amyloid-beta in Alzheimer's disease – a treatment approach used in cancer holds promise for dementia

Prof David Allsop (Faculty of Health & Medicine, Lancaster University), see https://www.sciencedaily.com/releases/2016/10/161020103528.htm – potential novel treatment as deliverable as nasal spray

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases

Prof Christian Hölscher (Faculty of Health & Medicine, Lancaster University). Potential drug repurposing for Parkinson's disease, Alzheimer's disease and motor neuron disease being explored – see https://www.alzheimers.org.uk/info/20053/research_projects/799/testing_type-2_diabetes_drugs_as_potential_treatments_for_alzheimers_disease

Could a Diabetes drug be useful in treating MND?

Prof Christian Hölscher (Faculty of Health & Medicine, Lancaster University) & Prof Hedley Emsley (Faculty of Health & Medicine, Lancaster University & Lancashire Teaching Hospitals) – clinical trial of liraglutide being developed in motor neuron disease, see https://mndresearch.wordpress.com/2016/08/02/could-a-diabetes-drug-be-useful-in-treating-mnd/, with support by the MND association for the related preclinical work

Testing the effect of the diabetes drug liraglutide in Alzheimer's disease

Dr Salman Karim (Lancashire Care NHS Foundation Trust) is working on this trial led by Dr Paul Edison – see https://www.alzheimers.org.uk/info/20053/research_projects/656/testing_the_effect_of_the_diabetes_drug_liraglutide_in_alzheimers_disease, with patients recruited through the NIHR Clinical Research Facility (joint venture with Lancashire Teaching Hospitals NHS Foundation Trust).

Better use of data to improve healthcare

Connected Health Cities North West Coast – part of a £20M 3-year project using information and technology to improve health services for patients across the North of England – this is a partnership between the NWC Academic Health Science Network, AIMES, Lancaster University and the University of Liverpool; its themes include epilepsy, see https://www.connectedhealthcities.org/ and http://www.innovationagencynwc.nhs.uk/connected-health-cities31

Resolving a key question in the early management of acute stroke – HeadPOST trial

UCLan was the UK coordinating centre, and Lancashire Teaching Hospitals NHS Foundation Trust the lead NHS trust in the UK for this international trial of head positioning in acute stroke, which showed no difference in disability outcomes in acute stroke patients who were laid flat vs those sitting up for the first 24 hours. Results were published in June 2018 in the New England Journal of Medicine (NEJM), see http://www.medscape.com/viewarticle/882050